The therapeutic potential of anti-CD20 "what do B-cells do?".
about
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases.Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.B cells and type 1 diabetes ...in mice and men.Inhibition of ICAM-1/LFA-1 interactions prevents B-cell-dependent anti-CD45RB-induced transplantation tolerance.Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.Rituximab for steroid-refractory chronic graft-versus-host disease.High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.Biologic therapies for inflammatory eye disease.Rituximab Downregulates Gene Expression Associated with Cell Proliferation, Survival, and Proteolysis in the Peripheral Blood from Rheumatoid Arthritis Patients: A Link between High Baseline Autophagy-Related ULK1 Expression and Improved Pain ControRituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy.Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.OX40+ T lymphocytes and IFN-γ are associated with American tegumentary leishmaniasis pathogenesis.CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.Why can't we find a new treatment for SLE?Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets.The late adverse events of rituximab therapy--rare but there!Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitisMonoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature.Effects of hepatitis C virus infection on the safety of chemotherapy for breast cancer patients.Elimination of autoreactive B cells in humanized SCID mouse model of SLE.Targeting B cells in systemic lupus erythematosus: not just déjà vu all over againRituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.Targeted silencing of DNA-specific B cells combined with partial plasma cell depletion displays additive effects on delaying disease onset in lupus-prone mice.Immunotherapy Strategies Against Multiple Myeloma.Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab.Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.Use of intravitreal rituximab for treatment of vitreoretinal lymphomaRituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature
P2860
Q30439017-C0276D23-78AA-4C9E-BEF3-576CF9EC709CQ33385389-46F55C01-B549-405E-8D09-B18359DDD176Q33586280-B0C9E6C2-F171-4165-B868-B9E710BBF7FAQ33735212-5C49D40A-F76E-47EC-8061-8B34776A4A38Q33926306-7CDE6471-A128-46E2-B54B-E25529F65645Q34107796-10CD1046-76AF-455C-AED5-824E8A211775Q34979203-4D74BC89-DC7D-4F56-8C27-A18DA8A25B6FQ35848933-2F763443-E7FE-45A3-A923-5AAAFB8A501DQ36211450-651A1DA9-59BB-4607-8672-7EE00BC425CBQ36501675-74DDDEF3-16E9-4FDE-9995-A2A979BBA4E5Q36556219-C59DBCF7-8356-4040-A45B-D5CF81FD3CDEQ36607310-FF6BBF53-99A5-45A3-B4AD-3EF5B91610BCQ36975931-3D39DC6D-A283-4477-9EED-CFAAAE08BF21Q36977705-31FD32DC-C968-4850-A4EE-ABF63C6853D9Q37034711-087FE382-5C3E-4A7D-A3AE-47E05C753524Q37236049-BC376666-D054-4A01-823C-95582B6F7871Q37436035-E6787D82-CACC-474D-B76F-8657EC78E92DQ37462485-0A50E897-4E6B-4CDC-981C-A6BD372B6FD3Q37640836-2E8B00A8-0372-4FC3-B281-5AB11512AEC0Q37968620-A1A96095-FE88-4776-851D-BE1719012EE0Q38154934-54E3453B-0502-429E-AB20-AF4B18847399Q38250103-FD7FDCC7-7404-45F1-A619-8B7F37B84B28Q38716531-272D2213-E4DB-4A4A-B970-B3F5DFC67600Q38905969-90A03B81-5C58-4562-A193-45C54EFE3900Q39266043-729BEDFD-EBB1-46C2-A463-5112DB213AFFQ39492463-30BA280F-8CE4-4E45-BD76-2763C9410344Q41847202-874C48D1-0CA8-4083-91DE-F37C23C675F8Q43042591-42CA666B-0B58-4E6F-A03B-12D9228F11FAQ46742155-2282071F-6824-41E7-AF32-935D143043E6Q46797870-514B0EC7-DDA6-4D7E-B086-E1CBDD67F76FQ49995864-6E913A51-D360-4E90-A859-8D6C61980AE8Q50668991-45F0BB20-8788-42A6-AA34-04B377582362Q50872769-212F1A5B-9069-45F5-871A-3D3D463F61BFQ58450924-DD41E685-ABA0-4D52-A5D1-755FBAF69FAAQ59126628-4E06EE0E-309A-4ACA-8F2A-511E28786AAA
P2860
The therapeutic potential of anti-CD20 "what do B-cells do?".
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The therapeutic potential of anti-CD20 "what do B-cells do?".
@ast
The therapeutic potential of anti-CD20 "what do B-cells do?".
@en
type
label
The therapeutic potential of anti-CD20 "what do B-cells do?".
@ast
The therapeutic potential of anti-CD20 "what do B-cells do?".
@en
prefLabel
The therapeutic potential of anti-CD20 "what do B-cells do?".
@ast
The therapeutic potential of anti-CD20 "what do B-cells do?".
@en
P1433
P1476
The therapeutic potential of anti-CD20 "what do B-cells do?".
@en
P2093
R John Looney
Robert Eisenberg
P304
P356
10.1016/J.CLIM.2005.08.006
P577
2005-09-19T00:00:00Z